OncoMatch/Clinical Trials/NCT05355051
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
Is NCT05355051 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Azacytidine and Pembrolizumab for hodgkin's lymphoma.
Treatment: Azacytidine · Pembrolizumab — This study is a Phase II single-center clinical trial designed to assess the efficacy, safety, and tolerability of pembrolizumab in combination with the 7-day regimen of azacitidine for the treatment of relapsed/refractory HL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Kidney function
adequate renal function per age unless related to the disease
Liver function
total bilirubin < 2x upper limit of normal (uln) unless increase is due to gilbert's disease, and ast < 3x uln unless considered due to lymphoma involvement
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05355051 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages